Skip to main content
Quest Diagnostics

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis

Authors: Briggs FBS, Mateen FJ, Schmidt H, Currie KM, Siefers HM, Crouthamel S, Bebo BF, Fiol J, Racke MK, O'Connor KC, Kolaczkowski LG, Klein P, Loud S, McBurney RN.

Citation: Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):e1104. doi: 10.1212/NXI.0000000000001104. Print 2022 Jan.

Specialties: Infectious disease, COVID-19, Neurology, 

Download key summary

Related publications

Publication
Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
Publication
Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies
Publication
Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management
Publication
Machine Learning Analysis Using RNA Sequencing to Distinguish Neuromyelitis Optica from Multiple Sclerosis and Identify Therapeutic Candidates

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.